secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0000950170-24-015913
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics reports FY2023 net loss of $121.8M; cash runway into 2026, pipeline milestones set for 2024
--------------------------------------------------------------------------------

- Cash and marketable securities $232.9M as of Dec 31, 2023, expected to fund operations into 2026.
- Net loss $121.8M ($2.02/share) for FY2023 vs $115.4M ($2.44/share) for FY2022.
- R&D expenses increased to $103.4M from $92.9M; G&A expenses decreased to $28.9M from $30.7M.
- PRT3789 (SMARCA2 degrader) on track for monotherapy dose escalation mid-2024; combo with docetaxel initiated H1 2024.
- PRT2527 (CDK9 inhibitor) to initiate combo with zanubrutinib Q1 2024; PRT7732 (oral SMARCA2 degrader) IND filing H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024015913/0000950170-24-015913-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024015913/prld-20240215.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-015913

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer